gliclazide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
gliclazide: clinical details
Prescribing considerations
- Confirm type 2 diabetes with residual beta-cell function and ability to maintain regular carbohydrate intake.
- Assess hypoglycaemia risks, including older age, malnutrition, fasting, strenuous exercise, alcohol use and renal, hepatic or endocrine disease.
- Consider a non-sulfonylurea alternative in G6PD deficiency because sulfonylureas can cause haemolytic anaemia.
- Check excipients and tablet-handling instructions for the exact product.
Contraindications and cautions
- Hypersensitivity to gliclazide, another sulfonylurea, a sulfonamide or a product excipient.
- Type 1 diabetes, diabetic ketoacidosis, diabetic pre-coma or diabetic coma.
- Severe renal or hepatic insufficiency.
- Concurrent miconazole treatment.
- Breastfeeding.
Monitoring
- Monitor HbA1c and blood glucose response, with additional checks after relevant changes.
- Ask about symptomatic, nocturnal, severe or unrecognised hypoglycaemia and review driving implications.
- Periodically reassess renal and hepatic function and treatment effectiveness.
- Investigate jaundice, persistent gastrointestinal symptoms, unusual bruising, infection symptoms or pallor.
Clinical pharmacology
Gliclazide stimulates glucose-responsive insulin secretion from pancreatic beta cells. It is highly protein bound, metabolised mainly in the liver and excreted predominantly as urinary metabolites. Modified-release formulations produce a more gradual exposure profile than standard-release tablets.
Formulation and product differences
- Standard-release and modified- or prolonged-release tablets have different release and administration characteristics.
- Splitting is permitted only when the exact product information says so.
- The selected standard-release tablet is scored and may be divided into equal portions.
- Switching formulations requires clinical review rather than tablet-for-tablet substitution.
gliclazide preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 30 mg, 60 mg
Tablet
Route: Oral
Strengths: 40 mg, 80 mg
gliclazide interactions
Interactions may cause hypoglycaemia, hyperglycaemia or altered effects of another medicine.
Miconazole, including oral gel or systemic treatment
Contraindicated because it can cause profound or prolonged hypoglycaemia, including coma.
Other diabetes medicines
Combined glucose-lowering effects may increase hypoglycaemia risk.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.